TY - JOUR
T1 - The Receptor for Hyaluronan-Mediated Motility (CD168) promotes inflammation and fibrosis after acute lung injury
AU - Cui, Zheng
AU - Liao, Jie
AU - Cheong, Naeun
AU - Longoria, Christopher
AU - Cao, Gaoyuan
AU - DeLisser, Horace M.
AU - Savani, Rashmin C.
N1 - Funding Information:
The studies in this manuscript were funded by the NIH R01 awards HL62868 , HL62472 and HL093535 , and U01 award HL075900 to RCS, and R01 award HL079090 to HMD. Additional funding was obtained from the William Buchanan Chair in Pediatrics and Children's Hospital Foundation grant (# 137 ) awarded to RCS.
Funding Information:
We would like to thank Dr. Eva Turley (Lawson Research Institute, London Regional Cancer Centre, London, Ontario, Canada) for the gift of the RHAMM KO mice and Dr. Christopher Glass (University of California, San Diego) for the gift of the SRA promoter plasmid used to generate transgenic mice. The studies in this manuscript were funded by the NIH R01 awards HL62868, HL62472 and HL093535, and U01 award HL075900 to RCS, and R01 award HL079090 to HMD. Additional funding was obtained from the William Buchanan Chair in Pediatrics and Children's Hospital Foundation grant (#137) awarded to RCS.
Funding Information:
The studies in this manuscript were funded by the NIH R01 awards HL62868, HL62472 and HL093535, and U01 award HL075900 to RCS, and R01 award HL079090 to HMD. Additional funding was obtained from the William Buchanan Chair in Pediatrics and Children's Hospital Foundation grant (#137) awarded to RCS.
Publisher Copyright:
© 2018 The Authors
PY - 2019/5
Y1 - 2019/5
N2 - Acute lung injury results in early inflammation and respiratory distress, and later fibrosis. The glycosaminoglycan hyaluronan (HA) and the Receptor for Hyaluronan-Mediated Motility (RHAMM, CD168) have been implicated in the response to acute lung injury. We hypothesized that, compared to wild type (WT) mice, RHAMM knockout (KO) mice would be protected from, whereas mice with macrophage-specific transgenic overexpression of RHAMM (TG) would have worse inflammation, respiratory distress and fibrosis after intratracheal (IT) bleomycin. Compared to WT mice, 10 days after IT bleomycin, RHAMM KO mice had less weight loss, less increase in respiratory rate, and fewer CD45+ cells in the lung. At day 28, compared to injured WT animals, injured RHAMM KO mice had lower M1 macrophage content, as well as decreased fibrosis as determined by trichrome staining, Ashcroft scores and lung HPO content. Four lines of transgenic mice with selective overexpression of RHAMM in macrophages were generated using the Scavenger Receptor A promoter driving a myc-tagged full length RHAMM cDNA. Baseline expression of RHAMM and CD44 was the same in WT and TG mice. By flow cytometry, TG bone marrow-derived macrophages (BMDM) had increased cell surface RHAMM and myc, but equal CD44 expression. TG BMDM also had 2-fold increases in both chemotaxis to HA and proliferation in fetal bovine serum. In TG mice, increased inflammation after thioglycollate-induced peritonitis was restricted to macrophages and not neutrophils. For lung injury studies, non-transgenic mice given bleomycin had respiratory distress with increased respiratory rates from day 7 to 21. However, TG mice had higher respiratory rates from 4 days after bleomycin and continued to increase respiratory rates up to day 21. At 21 days after IT bleomycin, TG mice had increased lung macrophage accumulation. Lavage HA concentrations were 6-fold higher in injured WT mice, but 30-fold higher in injured TG mice. At 21 days after IT bleomycin, WT mice had developed fibrosis, but TG mice showed exaggerated fibrosis with increased Ashcroft scores and HPO content. We conclude that RHAMM is a critical component of the inflammatory response, respiratory distress and fibrosis after acute lung injury. We speculate that RHAMM is a potential therapeutic target to limit the consequences of acute lung injury.
AB - Acute lung injury results in early inflammation and respiratory distress, and later fibrosis. The glycosaminoglycan hyaluronan (HA) and the Receptor for Hyaluronan-Mediated Motility (RHAMM, CD168) have been implicated in the response to acute lung injury. We hypothesized that, compared to wild type (WT) mice, RHAMM knockout (KO) mice would be protected from, whereas mice with macrophage-specific transgenic overexpression of RHAMM (TG) would have worse inflammation, respiratory distress and fibrosis after intratracheal (IT) bleomycin. Compared to WT mice, 10 days after IT bleomycin, RHAMM KO mice had less weight loss, less increase in respiratory rate, and fewer CD45+ cells in the lung. At day 28, compared to injured WT animals, injured RHAMM KO mice had lower M1 macrophage content, as well as decreased fibrosis as determined by trichrome staining, Ashcroft scores and lung HPO content. Four lines of transgenic mice with selective overexpression of RHAMM in macrophages were generated using the Scavenger Receptor A promoter driving a myc-tagged full length RHAMM cDNA. Baseline expression of RHAMM and CD44 was the same in WT and TG mice. By flow cytometry, TG bone marrow-derived macrophages (BMDM) had increased cell surface RHAMM and myc, but equal CD44 expression. TG BMDM also had 2-fold increases in both chemotaxis to HA and proliferation in fetal bovine serum. In TG mice, increased inflammation after thioglycollate-induced peritonitis was restricted to macrophages and not neutrophils. For lung injury studies, non-transgenic mice given bleomycin had respiratory distress with increased respiratory rates from day 7 to 21. However, TG mice had higher respiratory rates from 4 days after bleomycin and continued to increase respiratory rates up to day 21. At 21 days after IT bleomycin, TG mice had increased lung macrophage accumulation. Lavage HA concentrations were 6-fold higher in injured WT mice, but 30-fold higher in injured TG mice. At 21 days after IT bleomycin, WT mice had developed fibrosis, but TG mice showed exaggerated fibrosis with increased Ashcroft scores and HPO content. We conclude that RHAMM is a critical component of the inflammatory response, respiratory distress and fibrosis after acute lung injury. We speculate that RHAMM is a potential therapeutic target to limit the consequences of acute lung injury.
KW - Acute lung injury
KW - Fibrosis
KW - Hyaluronan
KW - Inflammation
KW - Knockout
KW - RHAMM
KW - Transgenic mice
UR - http://www.scopus.com/inward/record.url?scp=85051538053&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85051538053&partnerID=8YFLogxK
U2 - 10.1016/j.matbio.2018.08.002
DO - 10.1016/j.matbio.2018.08.002
M3 - Article
C2 - 30098420
AN - SCOPUS:85051538053
SN - 0945-053X
VL - 78-79
SP - 255
EP - 271
JO - Matrix Biology
JF - Matrix Biology
ER -